The expenditure on field force constitutes a major portion of biopharma companies' SG&A spend. Traditionally, field force sizing has been based on total HCP targets, behavioral, and attitudinal dimensions. However, in a post-COVID world, the majority of HCPs are seeking on-demand and digital information and are increasingly unable to see reps face to face. Biopharma companies need to rethink how they segment, target, and reach HCPs and move away from the traditional and now out-of-date HCP target lists with the rep as the primary channel. Effective field force training in product and disease in this evolving landscape necessitates adequate training on digital tools as well. To effectively handle these changes, it is important to strike a balance between the breadth and depth of deployment. Plus, it is critical to design incentive structures across rep-facing teams and internal teams to drive collaboration and delivery of the best possible HCP engagement strategy and execution, irrespective of channel.